drugset / Trial / NCT03074045

LCS16 vs. COC User Satisfaction and Tolerability Study

NCT03074045

Phase 3 Completed 145 enrolled Bayer
RandomizedParallel-groupOpen-labelTreatment

Summary

To evaluate user satisfaction in young nulliparous and parous women (18-29 years of age \[inclusive\]), using LCS16 compared to a COC over a period of 12 months.

Timeline

Start
2017-03-13
Primary completion
2018-09-03
Completion
2022-08-05

Publications

  • Results Suturina L.V., Dikke G.B. Experience in the use of low-dosed levonorgestrelcontaining intrauterine system Kyleena LNG and combined oral contraceptive containing 30 mcg ethinyl estradiol and 3 mg drospirenone in young women. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2021; 11: 230-236 (in Russian)

Drugs

EvaluationDrugModalityDoseRoute
Subject Levonorgestrel Small molecule 16 ug Other
Comparator drospirenone Unknown 3 mg Oral
Comparator ethinyl estradiol Small molecule 30 ug Oral

Indications

No indication recorded.